OP Team steps up
PharmNovo AB is pleased to announce that the company has strengthened the team when entering the clinical phase with PN6047. Tommy Nilsson takes on the role of CFO, and Jarkko Kalliomäki will support clinical management and work with the design and development of clinical studies.
In August, PharmNovo started clinical studies of its drug candidate PN6047 for the treatment of neuropathic pain, so-called nerve pain, after raising SEK 73 million in an issue led by Sciety earlier this summer.
Tommy Nilsson has a background as CFO at subsidiaries of Electrolux and Ericsson. He has worked as interim CFO for businesses in several industries for the past years. At PharmNovo, he will lead financial management and reporting, build up the company's routines and processes, and prepare the company for future follow-on financing.
Jarkko Kalliomäki is a specialist in pain and pain relief and holds an MD in Physiology. He has over ten years of experience as a Senior Clinical Research Physician at AstraZeneca R&D in Södertälje in several pain-related projects. He works as a consultant in rehabilitation medicine and pain relief at, among others, Sophiahemmet, PBM, and St. Göran's Hospital. Jarkko will support clinical management and work with the design and development of the clinical studies in close collaboration with Olof Breuer, CMO at PharmNovo.
OP Team steps up
PharmNovo AB is pleased to announce that the company has strengthened the team when entering the clinical phase with PN6047. Tommy Nilsson takes on the role of CFO, and Jarkko Kalliomäki will support clinical management and work with the design and development of clinical studies.
In August, PharmNovo started clinical studies of its drug candidate PN6047 for the treatment of neuropathic pain, so-called nerve pain, after raising SEK 73 million in an issue led by Sciety earlier this summer.
Tommy Nilsson has a background as CFO at subsidiaries of Electrolux and Ericsson. He has worked as interim CFO for businesses in several industries for the past years. At PharmNovo, he will lead financial management and reporting, build up the company's routines and processes, and prepare the company for future follow-on financing.
Jarkko Kalliomäki is a specialist in pain and pain relief and holds an MD in Physiology. He has over ten years of experience as a Senior Clinical Research Physician at AstraZeneca R&D in Södertälje in several pain-related projects. He works as a consultant in rehabilitation medicine and pain relief at, among others, Sophiahemmet, PBM, and St. Göran's Hospital. Jarkko will support clinical management and work with the design and development of the clinical studies in close collaboration with Olof Breuer, CMO at PharmNovo.
Latest news
View all
Positive final Phase I results
The final results from the Phase I clinical for our neuropathic pain drug candidate PN6047, demonstrates safety and tolerability and a lack of the adverse effects commonly associated with conventional opioids. The findings from the Phase I trial show that PN6047 is safe and well-tolerated at the doses tested, with no serious adverse events reported.
Read more
Meet Bengt von Mentzer, founder and Chief scientific advisor
Bengt von Mentzer founded PharmNovo 16 years ago, and today, his visionary approach and scientific process still drive the development of the groundbreaking compound PN6047. At the intersection of innovation and scientific leadership, Bengt von Mentzer is paving the way for how to reshape the landscape of chronic pain treatment.
Read more
NIDA funds studies
The US National Institute of Drug Abuse (NIDA) has funded a project investigating the drug candidate PN6047, a novel and highly selective Delta Opioid Receptor Agonist (DORA), represents a unique approach to addressing this medical challenge.
Read more
Meet Olof Breuer, MD, Clinical pharmacology lead
Olof Breuer's presence at PharmNovo exemplifies the company's commitment to pioneering advancements in pain relief. His visionary approach, honed through years of experience, positions him as a driving force in the quest for novel concepts in neuropathic pain relief.
Read more